Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

The stock's fall snapped a four-day winning streak.

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

With the stock currently trading at Rs 641.90, Syngene International showcases a moderate uptrend in today's session, amidst ...

MphasiS's stock performance today reflects a positive shift, with a notable price increase. Investors and market participants ...

analysis of the Phase 3... By Nate Raymond (NSE:RYMD) (Reuters) - Pfizer (NYSE:PFE) has resolved a lawsuit by a conservative group that alleged that a... Investing.com - Healthcare and vaccine ...

Online vehicle auction company Copart (NASDAQ:CPRT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose ...